Citius Oncology, Inc. (CTOR)
NASDAQ: CTOR · Real-Time Price · USD
0.9000
+0.0097 (1.09%)
At close: May 30, 2025, 4:00 PM
0.8542
-0.0458 (-5.09%)
After-hours: May 30, 2025, 5:32 PM EDT

Citius Oncology Statistics

Total Valuation

Citius Oncology has a market cap or net worth of $64.40 million. The enterprise value is $68.20 million.

Market Cap 64.40M
Enterprise Value 68.20M

Important Dates

The last earnings date was Wednesday, May 14, 2025, after market close.

Earnings Date May 14, 2025
Ex-Dividend Date n/a

Share Statistics

Citius Oncology has 71.55 million shares outstanding. The number of shares has increased by 3.82% in one year.

Current Share Class 71.55M
Shares Outstanding 71.55M
Shares Change (YoY) +3.82%
Shares Change (QoQ) n/a
Owned by Insiders (%) n/a
Owned by Institutions (%) 0.17%
Float 5.50M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio n/a
Forward PS n/a
PB Ratio 1.81
P/TBV Ratio 1.81
P/FCF Ratio n/a
P/OCF Ratio 509.66
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 0.36, with a Debt / Equity ratio of 0.11.

Current Ratio 0.36
Quick Ratio n/a
Debt / Equity 0.11
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage n/a

Financial Efficiency

Return on equity (ROE) is -93.64% and return on invested capital (ROIC) is -53.05%.

Return on Equity (ROE) -93.64%
Return on Assets (ROA) -22.41%
Return on Invested Capital (ROIC) -53.05%
Return on Capital Employed (ROCE) -60.35%
Revenue Per Employee n/a
Profits Per Employee n/a
Employee Count n/a
Asset Turnover n/a
Inventory Turnover n/a

Taxes

In the past 12 months, Citius Oncology has paid $816,480 in taxes.

Income Tax 816,480
Effective Tax Rate n/a

Stock Price Statistics

The stock price has decreased by -92.06% in the last 52 weeks. The beta is -0.17, so Citius Oncology's price volatility has been lower than the market average.

Beta (5Y) -0.17
52-Week Price Change -92.06%
50-Day Moving Average 0.78
200-Day Moving Average 1.16
Relative Strength Index (RSI) 56.56
Average Volume (20 Days) 47,181

Short Selling Information

The latest short interest is 47,100, so 0.07% of the outstanding shares have been sold short.

Short Interest 47,100
Short Previous Month 71,001
Short % of Shares Out 0.07%
Short % of Float 0.86%
Short Ratio (days to cover) 0.65

Income Statement

Revenue n/a
Gross Profit n/a
Operating Income -25.16M
Pretax Income n/a
Net Income -25.98M
EBITDA n/a
EBIT -25.16M
Earnings Per Share (EPS) -$0.37
Full Income Statement

Balance Sheet

The company has $112 in cash and $3.80 million in debt, giving a net cash position of -$3.80 million or -$0.05 per share.

Cash & Cash Equivalents 112
Total Debt 3.80M
Net Cash -3.80M
Net Cash Per Share -$0.05
Equity (Book Value) 35.64M
Book Value Per Share 0.50
Working Capital -31.70M
Full Balance Sheet

Cash Flow

Operating Cash Flow 126,353
Capital Expenditures n/a
Free Cash Flow n/a
FCF Per Share n/a
Full Cash Flow Statement

Margins

Gross Margin n/a
Operating Margin n/a
Pretax Margin n/a
Profit Margin n/a
EBITDA Margin n/a
EBIT Margin n/a
FCF Margin n/a

Dividends & Yields

Citius Oncology does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -3.82%
Shareholder Yield -3.82%
Earnings Yield -40.34%
FCF Yield n/a

Analyst Forecast

The average price target for Citius Oncology is $6.00, which is 566.67% higher than the current price. The consensus rating is "Buy".

Price Target $6.00
Price Target Difference 566.67%
Analyst Consensus Buy
Analyst Count 2
Revenue Growth Forecast (5Y) n/a
EPS Growth Forecast (5Y) n/a
Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a

Scores

Altman Z-Score n/a
Piotroski F-Score 3